Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Assessing the Safety & Efficacy of an Affordable Fracture External Fixation System (AEFIX)

10 de noviembre de 2026 actualizado por: Beth Israel Deaconess Medical Center

AEFIX Trial: A Multicenter, Open-Label, Randomized Pivotal (Phase III) Clinical Trial Assessing the Safety and Efficacy of a Novel, Affordable External Fixation System for the Management of Femur and Tibia Fractures in Adults

The goal of this clinical trial is to learn whether AEFIX, a new low-cost external fixation system, works as well as the external fixators currently used in Rwandan public hospitals to hold broken thigh (femur) and shin (tibia) bones in position in adults. External fixation uses metal pins placed into the bone and connected by clamps and rods outside the body. It is commonly used for severe fractures, including open fractures, that cannot safely be treated with internal plates or rods right away.

The main questions it aims to answer are:

  • Does AEFIX keep the broken bone in position as well as standard external fixators, as measured on X-rays taken after surgery and again before the fixator is removed?
  • How do complications, quality of life, and fracture healing compare between the two groups?

Researchers will compare AEFIX to the external fixation systems already used as standard care at each participating hospital to see whether AEFIX is no worse than these systems at keeping the bone in place.

Participants will:

  • Be randomly assigned, like a coin toss, to receive either AEFIX or the standard external fixator during their planned fracture surgery
  • Have X-rays after surgery and before the external fixator is removed
  • Return for follow-up visits about 6 weeks, 3 months, 6 months, and 12 months after surgery, where the study team will check pin sites, healing, pain, and ability to bear weight, and ask questions about quality of life
  • Receive reimbursement for transport costs to attend follow-up visits

About 150 adults will take part at up to five hospitals in Rwanda.

Descripción general del estudio

Descripción detallada

Background Musculoskeletal trauma is common and rising in Rwanda, driven largely by road traffic injuries, and open fractures of the tibia are among the most frequent and serious injuries treated at referral hospitals. External fixation is the standard of care for temporary, and sometimes definitive, stabilization of fractures that cannot safely undergo internal fixation because of infection risk, soft tissue injury, or patient instability. Industry-standard external fixator clamps cost approximately 500 USD each, which limits their availability in public hospitals in low- and middle-income countries, where many fixators in use are donated or reprocessed. AEFIX is an affordable modular external fixation system (approximately 15 USD per clamp) made from medical-grade hard coat anodized aluminum and stainless steel. Laboratory mechanical testing has shown performance comparable to industry-standard clamps. This trial evaluates whether AEFIX is non-inferior to locally available external fixation systems in routine clinical practice in Rwanda.

Design This is a multicenter, pragmatic, open-label, parallel-arm randomized controlled trial with a non-inferiority design. Eligible participants are randomized 1:1 in the operating theatre, after final confirmation of eligibility, using a centralized web-based randomization system. Participants in the comparator arm receive the external fixation system routinely used at the participating site. The brand and model of each comparator construct, and whether components were previously used and reprocessed, are recorded for every participant, and each construct is photographed at application. Comparator systems at participating sites are predominantly Stryker Hoffmann 3. All participating surgeons complete a dedicated instructional course on the AEFIX technique before using the device.

Staged site activation Enrollment begins at the University Teaching Hospital of Kigali (CHUK) and the University Teaching Hospital of Butare (CHUB). Approximately the first 70 participants constitute an initial feasibility stage assessing recruitment rate (target of more than 3 participants per site per month), retention, and adherence to randomized allocation. Three district hospitals (Kabgayi, Kibagabaga, and Kibogora) will be activated following review of feasibility data by the independent Data and Safety Monitoring Committee (DSMC), or earlier if recruitment at CHUK and CHUB remains below target after three months of enrollment.

Sample size Assuming approximately 95% maintenance of fracture reduction in both arms, 74 participants (37 per arm) provide 90% power to demonstrate non-inferiority with a one-sided alpha of 0.05 and a non-inferiority margin of 15%. Allowing for up to 50% loss to follow-up, the trial will enroll 150 participants (75 per arm).

Statistical analysis The primary analysis follows the intention-to-treat principle and includes all comparator systems, reflecting routine practice. Per-protocol and as-treated analyses will assess robustness given the possibility of intraoperative device crossover. A pre-specified secondary analysis repeats the non-inferiority comparison among participants treated with AEFIX or Stryker Hoffmann 3, the predominant comparator, to provide a direct device-to-device comparison. Missing data will be handled by multiple imputation under a missing-at-random assumption, with sensitivity analyses. The trial biostatistician remains blinded to treatment allocation until database lock; the allocation key is held by an independent data manager with no role in outcome assessment or analysis.

Safety oversight An independent five-member DSMC with expertise in surgery, clinical research, research ethics, and biostatistics, based in Rwanda and the United States, meets quarterly and as needed. DSMC members have no financial relationship with the manufacturer of the investigational device or of the comparator devices. Causality of all adverse events is determined by the DSMC, independently of the study investigators and the device developer. Serious adverse device effects are reported to the Rwanda Food and Drugs Authority and the Rwanda National Research Ethics Committee in accordance with national requirements and ISO 14155:2020.

Conflict of interest The AEFIX device is developed and donated by SONA Global, a nonprofit organization founded by a study co-investigator, who receives no income, compensation, or equity from the organization.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

150

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Jean de la Croix Allen Ingabire, MD, PhD
  • Número de teléfono: +250 788 549 975
  • Correo electrónico: ijea2000@gmail.com

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Huye, Ruanda
        • University Teaching Hospital of Butare (CHUB)
        • Contacto:
          • Jean de la Croix Allen Ingabire, MD, PhD
          • Número de teléfono: +250 788 549 975
          • Correo electrónico: ijea2000@gmail.com
      • Kigali, Ruanda
        • University Teaching Hospital of Kigali (CHUK)
        • Contacto:
          • Jean Claude Byiringiro, MD
          • Número de teléfono: +250 788 868 240
          • Correo electrónico: jcbyiringiro@gmail.com
        • Contacto:
        • Investigador principal:
          • Marie Grace Kansayisa, MD
      • Kigali, Ruanda
        • Kibagabaga District Hospital
        • Contacto:
          • Jean de la Croix Allen Ingabire, MD, PhD
          • Número de teléfono: +250 788 549 975
          • Correo electrónico: ijea2000@gmail.com
      • Muhanga, Ruanda
        • Kabgayi District Hospital
        • Contacto:
          • Jean de la Croix Allen Ingabire, MD, PhD
          • Número de teléfono: +250 788 549 975
          • Correo electrónico: ijea2000@gmail.com
      • Nyamasheke, Ruanda
        • Kibogora District Hospital
        • Contacto:
          • Jean de la Croix Allen Ingabire, MD, PhD
          • Número de teléfono: +250 788 549 975
          • Correo electrónico: ijea2000@gmail.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age 18 years or older.
  • Closed or open fracture of the femur and/or tibia, including fractures of the proximal femur, femoral diaphysis, extra-articular and intra-articular fractures of the distal femur and proximal tibia, tibial diaphysis, and extra-articular and intra-articular fractures of the distal tibia, including pilon and ankle fractures.
  • Fracture not amenable to internal fixation due to risk of infection, inadequate soft tissue coverage, severe soft tissue trauma, or hemodynamic instability, and therefore indicated for external fixation by the treating surgeon.
  • All planned surgeries to be performed by a participating surgeon or delegate at a study site (no pre-operative plan for transfer to another facility or surgeon after external fixation).
  • Informed consent obtained from the patient or, if the patient is unable to consent because of their injury, from a healthcare proxy or legally authorized representative.

Exclusion Criteria:

  • Established fracture malunion or nonunion, including any patient undergoing correction of deformity or management of a malunion, nonunion, or delayed union.
  • Established chronic osteomyelitis or pathologic fracture.
  • Limb deformity correction or bone transport.
  • Periprosthetic fracture.
  • Incarceration.
  • Current enrollment in another study that does not permit co-enrollment.
  • Unable to provide informed consent due to language barriers.
  • Prior enrollment in this study.
  • Fracture pattern or anatomical condition precluding safe placement of Schanz pins in established anatomical safe zones, as determined intraoperatively by the participating surgeon.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: AEFIX External Fixation

Participants receive fracture external fixation using the AEFIX system, an affordable modular external fixator consisting of AEFIX clamps (hard coat anodized aluminum), 11 mm aluminum connecting rods, and 5 mm Schanz pins. Components are steam sterilized on site before use. Pins are placed bicortically in anatomical safe zones and connected by clamps and rods in a unilateral double-rod or modular frame construct. The fixator remains in place until removal by the treating surgeon for staged conversion to internal fixation or after definitive treatment.

Investigational modular external fixation system (clamps, connecting rods, and Schanz pins) designed for affordability in resource-limited settings. Clamps are made of medical-grade hard coat anodized aluminum and stainless steel, supplied non-sterile, and steam sterilized before single use. Manufactured by an ISO 13485-certified contract manufacturer for SONA Global.

Comparador activo: Standard of Care External Fixation

Participants receive fracture external fixation using the locally available external fixation system routinely used as standard of care at the participating hospital, most commonly donated or reprocessed modular systems from established manufacturers (predominantly Stryker Hoffmann 3; also DePuy Synthes and others). The brand and model of each comparator construct, and whether components were previously used and reprocessed, are recorded for every participant, and each construct is photographed at application. The fixator remains in place until removal by the treating surgeon for staged conversion to internal fixation or after definitive treatment.

Commercially available modular external fixation systems already in routine clinical use at participating hospitals, not supplied by the sponsor. Device brand, model, and reprocessing history are documented for each participant.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Loss of Fracture Reduction
Periodo de tiempo: From initial postoperative radiograph (within 24 hours of external fixator application) to final radiograph (within 48 hours before external fixator removal), up to 12 months

Proportion of participants with loss of fracture reduction, defined as any of the following between the initial postoperative radiograph and the final radiograph before external fixator removal: angular deformity change greater than 5 degrees in the coronal or sagittal plane; translational displacement greater than 10 millimeters in any plane; or increase in fracture gap greater than 10 millimeters, measured using calibrated digital radiographic tools. Participants with more than one fracture treated with external fixation are counted as having loss of reduction if it occurs in any treated fracture. Non-inferiority of AEFIX relative to locally available external fixation systems is assessed using a pre-specified margin of 15% and a one-sided alpha of 0.05.

From initial postoperative radiograph (within 24 hours of external fixator application) to final radiograph (within 48 hours before external fixator removal), up to 12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants With Clinical Complications, by Type
Periodo de tiempo: 6 weeks, 3 months, 6 months, and 12 months after initial surgery

Clinical complications include pin tract infection, superficial infection, deep infection, iatrogenic neurovascular injury, malunion, nonunion, amputation, and death, reported as the number of participants experiencing each complication per treatment arm.

6 weeks, 3 months, 6 months, and 12 months after initial surgery
Health-Related Quality of Life (EQ-5D-5L Index Score)
Periodo de tiempo: 6 weeks, 3 months, 6 months, and 12 months after initial surgery

The EQ-5D-5L measures five dimensions of health (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels, and is summarized as an index score where 1 represents full health and 0 represents a state equivalent to death; values below 0 are possible. Higher scores indicate better health-related quality of life. A difference of 0.074 is considered the minimum clinically important difference.

6 weeks, 3 months, 6 months, and 12 months after initial surgery
Functional Fracture Healing (Functional IndeX for Trauma [FIX-IT] Score)
Periodo de tiempo: 6 weeks, 3 months, 6 months, and 12 months after initial surgery

The FIX-IT score assesses ability to bear weight (0 to 6 points) and pain at the fracture site (0 to 6 points), for a total score ranging from 0 to 12. Higher scores indicate better clinical fracture healing and function. A change of 2 or more points is considered clinically meaningful.

6 weeks, 3 months, 6 months, and 12 months after initial surgery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Jean de la Croix Allen Ingabire, MD, PhD, University of Rwanda

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de marzo de 2029

Finalización del estudio (Estimado)

1 de febrero de 2030

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified individual participant data underlying the results reported in publications, including primary and secondary outcome data and baseline characteristics, will be made available to qualified researchers upon reasonable request. Data are owned by the University of Rwanda; sharing is subject to approval by the University of Rwanda and the Rwanda National Research Ethics Committee, compliance with Rwandan data protection law, and execution of a data use agreement.

Marco de tiempo para compartir IPD

Beginning 6 months after publication of the primary results and ending 5 years after publication.

Criterios de acceso compartido de IPD

Requests from qualified researchers with a methodologically sound proposal will be reviewed by the study investigators and the University of Rwanda. Approved requesters must sign a data use agreement prohibiting re-identification and limiting use to the approved proposal. Requests should be directed to the Principal Investigator.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir